CDC logo Tuberculosis Information CD-ROM   Image of people
spacer image

Table 2. Regimen Options for Treatment of Latent TB Infection for Persons with HIV Infection, 2000

Updated August 2003
Drug Regimen Comments
Daily Twice Weekly

9 months

9 months

9 months

9 months

Minimum of 270 doses administered within 12 months

Twice-weekly regimens should consist of at least 76 doses administered within 12 months.

Directly observed treatment (DOT) of LTBI should be used when twice-weekly dosing is used.

INH can be administered concurrently with NRTIs, PIs, or NNRTIs

Contraindicated for persons who have active hepatitis and end-stage liver disease

RIF 4 months 4 months Not recommended Minimum of 120 doses administered within 6 months

For persons who are contacts of patients with INH-resistant, RIF-susceptible TB

Acceptable alternative; may be used for patients who cannot tolerate INH

Most PIs or delavirdine should not be administered concurrently with RI; Rifabutin with appropriate dose adjustments, can be used with PIs (saquinavir should be augmented with ritonavir) and NNRTIs (except delavirdine).

RIF and PZA Should generally not be offered

A TB/LTBI expert should be consulted prior to the use of this regimen.

RFB and PZA Should generally not be offered


INH - isoniazid; PZA - pyrazinamide; RFB - rifabutin; RIF- rifampin; DOPT- directly observed preventive therapy; PIs - protease inhibitors; NNRTIs - nonnucleoside reverse transcriptase inhibitors; NRTIs - nucleoside reverse transcriptase inhibitors; HIV - human immunodeficiency virus; LTBI - latent TB infection

Note: For patients whose organisms are resistant to 1 or more drugs, administer at least 2 drugs to which there is demonstrated susceptibility and consult a TB medical expert. Clinicians should review the drug-susceptibility pattern of the M. tuberculosis strain isolated from the infecting source-patient before choosing a preventive therapy regimen.


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination -

Please send comments/suggestions/requests to:, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333